Virios Therapeutics, Inc.
VIRI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,530,913 | $1,728 | $8,070 | $10,796 |
| G&A Expenses | $8,696,335 | $3,719 | $4,246 | $4,845 |
| SG&A Expenses | $8,696,335 | $3,719 | $4,246 | $4,845 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $67 | $0 |
| Operating Expenses | $12,227,248 | $5,447 | $12,315 | $15,641 |
| Operating Income | -$12,227,248 | -$5,447 | -$12,315 | -$15,641 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$122,979 | $151 | $67 | -$319 |
| Pre-Tax Income | -$12,350,227 | -$5,296 | -$12,248 | -$15,960 |
| Tax Expense | $503 | $0 | -$67 | $0 |
| Net Income | -$12,863,829 | -$5,296 | -$12,180 | -$15,960 |
| % Margin | – | – | – | – |
| EPS | -12.52 | -0.28 | -1.1 | -1.92 |
| % Growth | -4,371.4% | 74.5% | 42.7% | – |
| EPS Diluted | -12.52 | -0.28 | -1.1 | -1.92 |
| Weighted Avg Shares Out | 1,027,788 | 18,777 | 11,070 | 8,329 |
| Weighted Avg Shares Out Dil | 1,027,788 | 18,777 | 11,070 | 8,329 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $151 | $67 | $6 |
| Interest Expense | $92,192 | $0 | $0 | $6 |
| Depreciation & Amortization | $0 | $5,447 | $12,315 | $15,641 |
| EBITDA | -$12,227,248 | $151 | -$12,315 | -$15,641 |
| % Margin | – | – | – | – |